市場調査レポート
商品コード
1182436

体外診断の世界市場:製品/サービス別 (装置、キット、ソフトウェア)・技術別 (イムノアッセイ、血液検査、尿検査)・用途別 (糖尿病、腫瘍、心臓病、感染症)・エンドユーザー別 (病院、診療所) の将来予測 (2027年まで)

In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 453 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
体外診断の世界市場:製品/サービス別 (装置、キット、ソフトウェア)・技術別 (イムノアッセイ、血液検査、尿検査)・用途別 (糖尿病、腫瘍、心臓病、感染症)・エンドユーザー別 (病院、診療所) の将来予測 (2027年まで)
出版日: 2023年01月05日
発行: MarketsandMarkets
ページ情報: 英文 453 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の体外診断の市場規模は、2022年の1,158億米ドルから、2027年には1,447億米ドルにまで、4.6%のCAGRで成長する、と予測されています。

疾患の早期診断のためにPoC機器や迅速検査の採用が進んでいることや、早期診断・治療による予防治療に対する政府の取り組みや資金調達が増加していることなどが、市場の成長を後押ししています。

製品/サービス別では、試薬・キット市場が最大のシェアを占めています。病気の検査やモニタリングのために、さまざまなハンドヘルド機器や検査室用の複雑なIVD機器に、試薬が繰り返し使用されていることが、このセグメントの成長を促す主な要因となっています。

技術別に見ると、2021年にイムノアッセイ/免疫化学のセグメントが最大のシェアを占めています。

用途別では、感染症分野が最大のシェアを占めています。その要因として、多剤耐性感染症の蔓延の増加に伴い、効果的な診断ツールに対するニーズが高まっていることなどがあります。

エンドユーザー別では、PoC検査の分野が、予測期間中に最も高いCAGRを記録すると予想されています。この市場の成長は、遠隔地における検査や病気の早期診断のニーズが高まっていることに起因しています。また、PoC検査における技術進歩により、より信頼性が高く正確な検査が可能となり、市場が成長しつつあります。

地域別に見ると、アジア太平洋が予測期間中、最も高いCAGRで成長する見通しです。この地域の成長の背景には、より良い医療サービスに対する需要の高まり、新興国市場の医療インフラの急速な発展、予防医療方法に関する政府の取り組みの増加などがあります。

当レポートでは、世界の体外診断 (IVD) の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、製品/サービス別・用途別・用途別・エンドユーザー別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 産業動向
    • 臨床検査技術の自動化
    • 実験室試験用のマイクロフルイディクスベースのPOCおよびLAB-ON-A-CHIP診断デバイス
    • 試薬レンタル契約数の増加
    • 技術ベースのソリューションにシフトする収益源
  • ポーターのファイブフォース分析
  • 規制機関、政府機関、その他の組織
  • 規制分析
  • 主な会議とイベント (2023年)
  • 特許分析
  • 貿易分析
  • エコシステム分析
  • バリューチェーン分析
  • サプライチェーン分析
  • 価格分析
  • 技術分析
  • ケーススタディ
  • 主な利害関係者と購入基準
  • 体外診断市場に対する不況の影響 (2021年~2024年)
  • 体外診断規制 (IVDR) が治験に与える影響

第6章 体外診断市場:製品/サービス別

  • イントロダクション
  • 試薬・キット
  • 装置
    • 全自動装置
    • 半自動装置
    • その他の装置
  • データ管理ソフトウェア
  • サービス

第7章 体外診断市場:技術別

  • イントロダクション
  • イムノアッセイ (免疫測定)/免疫化学
    • ELISA (酵素結合免疫吸着測定法)
    • ラジオイムノアッセイ
    • 迅速検査
    • ウェスタンブロッティング
    • ELIspot (酵素結合イムノスポットアッセイ)
  • 臨床化学
    • 基礎代謝パネル (BMP)
    • 肝臓パネル
    • 腎臓プロファイル
    • 脂質プロファイル
    • 甲状腺機能パネル
    • 電解質パネル
    • 特殊化学検査
  • 分子診断
    • ポリメラーゼ連鎖反応 (PCR)
    • 等温核酸増幅技術 (INAAT)
    • ハイブリダイゼーション
    • DNAシーケンシング、次世代シーケンシング (NGS)
    • マイクロアレイ
    • その他の分子診断技術
  • 血液検査
  • 微生物検査
  • 凝固・止血
  • 尿検査
  • その他の技術

第8章 体外診断市場:用途別

  • イントロダクション
  • 感染症
  • 糖尿病
  • 腫瘍
  • 心臓病
  • 薬物検査/ファーマコゲノミクス
  • HIV/エイズ
  • 自己免疫疾患
  • 腎臓学
  • その他の用途

第9章 体外診断市場:エンドユーザー別

  • イントロダクション
  • 病院室
  • 臨床検査室
    • 大規模検査室
    • 中規模検査室
    • 小規模検査室
  • PoC (ポイントオブケア) 検査センター
  • 患者
  • 教育機関
  • その他のエンドユーザー

第10章 体外診断市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • インドネシア
    • 他のアジア太平洋諸国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • 他のラテンアメリカ諸国
  • 中東・アフリカ
    • サウジアラビア
    • 他の中東・アフリカ諸国

第11章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 主要企業の収益シェア分析
  • 市場シェア分析
    • 市場シェア分析:技術別
  • 主要企業の研究開発 (R&D) 評価
  • 競合ベンチマーキング
  • 企業評価クアドラント
  • 企業評価クアドラント:中小企業/スタートアップ向け
  • 企業のフットプリント分析
  • 競合シナリオ
    • 製品の発売と承認
    • 資本取引
    • その他の動向

第12章 企業プロファイル

  • 主要企業
    • ROCHE DIAGNOSTICS
    • DANAHER CORPORATION
    • ABBOTT LABORATORIES, INC.
    • SIEMENS HEALTHINEERS
    • SYSMEX CORPORATION
    • THERMO FISHER SCIENTIFIC, INC.
    • BECTON, DICKINSON AND COMPANY
    • BIOMERIEUX SA
    • BIO-RAD LABORATORIES, INC.
    • AGILENT TECHNOLOGIES, INC.
    • QIAGEN N.V.
    • QUIDEL CORPORATION
    • DIASORIN S.P.A.
    • ILLUMINA, INC.
    • HOLOGIC, INC.
  • その他の企業
    • DEVYSER
    • PERKINELMER INC.
    • CHEMBIO DIAGNOSTICS, INC.
    • SURMODICS, INC.
    • MENARINI SILICON BIOSYSTEMS
    • SPEEDX PTY. LTD.
    • GENSPEED BIOTECH GMBH
    • ACCELERATE DIAGNOSTICS, INC.
    • MERCK KGAA
    • CARIS LIFE SCIENCES, INC.

第13章 付録

目次
Product Code: MD 3609

The in vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%. The growing adoption of point-of-care devices and rapid tests for early disease diagnosis, and the rising government initiatives & funding for preventive cure with early diagnosis and treatment drive growth in the market.

The reagents & kits segment accounted for the largest share of the market

On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of the IVD market in 2021. The recurring use of reagents in various handheld and complex laboratory IVD instruments for disease testing and monitoring is a major factor driving the growth of this segment.

The immunoassay/immunochemistry segment accounted for the largest share of the IVD technology market

Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The immunoassay/immunochemistry segment accounted for the largest share of the IVD technologies market in 2021. Immunoassays are mostly preferred for immunodiagnostic techniques over other diagnostic methods due to the ability of these tests to provide rapid results, and simplistic sample preparation needs with minimal human intervention.

The infectious disease segment accounted for the largest share of the IVD market

On the basis of application, the IVD market is segmented based on application into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications. In 2021, the infectious diseases segment accounted for the largest share of the IVD market. The large share of this segment can be attributed to the growing need for effective diagnostic tools for the rising prevalence of multi-drug-resistant infectious diseases.

Point-of care testing to register the highest growth during the forecast period

Based on end users, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. Point-of-care segment to register the highest CAGR during the forecast period. The growth in this market is attributed to the increasing need for testing and early disease diagnosis of diseases in remote locations. Moreover, the technological advancements in the point-of- care testing, make them more reliable and accurate driving the growth of this market.

APAC is expected to grow at the highest CAGR during the forecast period

The IVD market in the Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region can be attributed to the rising demand for better healthcare services, rapid development in the healthcare infrastructure of emerging markets, and the growing government initiatives on preventive care methods.

A breakdown of the primary participants for the in vitro diagnostics market referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation: C-level-35%, Director Level-25%, and Others-40%
  • By Region: North America-45%, Europe-30%, Asia Pacific-20%, Latin America - 3%, Middle East & Africa - 2%

The prominent players in the global in vitro diagnostics market are Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMerieux SA (France), Agilent Technologies, Inc. (US), Chembio Diagnostics, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).

Research Coverage

The report analyzes the market for various in vitro diagnostics products & services and their adoption pattern. It aims at estimating the market size and future growth potential of the in vitro diagnostics market and different segments such as by technology, application, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, services, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global in vitro diagnostics market.
  • Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global in vitro diagnostics market.
  • Market Development: Comprehensive information on the lucrative emerging regions by product & services, technology, application, end users, and region.
  • Market Diversification: Exhaustive information about new products & services, growing geographies, and recent developments in the global in vitro diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global in vitro diagnostics market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • 1.2.2 MARKET SEGMENTATION
    • FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED
  • 1.3 CURRENCY CONSIDERED
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
    • FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2021)
    • FIGURE 8 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2021)
    • FIGURE 9 IVD MARKET: TOP-DOWN APPROACH
    • FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2022-2027)
    • FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 16 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 17 GEOGRAPHIC SNAPSHOT OF IVD MARKET

4 PREMIUM INSIGHTS

  • 4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 18 RISING INCIDENCE OF INFECTIOUS DISEASES AND GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED ANALYZERS TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)
    • FIGURE 19 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
  • 4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • 4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX
    • FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING VS. DEVELOPED MARKETS
    • FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 23 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases
    • TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019-2050)
      • 5.2.1.2 Gradual shift from centralized testing to point-of-care testing
      • 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies
      • 5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers
    • TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2020-2022)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Introduction of disease-specific biomarkers and tests
    • TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
      • 5.2.3.2 Growing significance of companion diagnostics
      • 5.2.3.3 Growth opportunities in emerging markets
    • TABLE 6 RECENT DEVELOPMENTS IN EMERGING MARKETS
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory & legal guidelines
    • FIGURE 24 IVDR: KEY AREAS OF IMPACT
      • 5.2.4.2 Operational barriers
    • TABLE 7 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES
    • 5.3.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING
    • 5.3.3 RISING NUMBER OF REAGENT RENTAL AGREEMENTS
    • 5.3.4 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS
    • FIGURE 25 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS
  • 5.4 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 PORTER'S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    • 5.4.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.4.2 BARGAINING POWER OF SUPPLIERS
    • 5.4.3 BARGAINING POWER OF BUYERS
    • 5.4.4 THREAT OF NEW ENTRANTS
    • 5.4.5 THREAT FROM SUBSTITUTES
  • 5.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6 REGULATORY ANALYSIS
    • 5.6.1 NORTH AMERICA
      • 5.6.1.1 US
    • TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
    • FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
      • 5.6.1.2 Canada
    • FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
    • 5.6.2 EUROPE
    • TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 28 EUROPE: IVDR TIMELINE
    • 5.6.3 ASIA PACIFIC
      • 5.6.3.1 Japan
    • FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
    • TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
    • TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.6.3.2 China
    • TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.6.3.3 India
    • FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES
      • 5.6.3.4 South Korea
    • TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.6.3.5 Indonesia
    • TABLE 16 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
    • 5.6.4 RUSSIA
    • TABLE 17 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 5.6.5 MIDDLE EAST & AFRICA
      • 5.6.5.1 Saudi Arabia
    • TABLE 18 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.6.5.2 Africa
    • 5.6.6 LATIN AMERICA
      • 5.6.6.1 Mexico
    • FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 19 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.6.6.2 Brazil
  • 5.7 KEY CONFERENCES & EVENTS IN 2023
    • TABLE 20 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 32 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011-DECEMBER 2022)
    • FIGURE 33 TOP APPLICANT JURISDICTIONS FOR IVD PATENTS (JANUARY 20211-DECEMBER 2022)
    • 5.8.2 PATENT PUBLICATION TRENDS FOR IN VITRO DIAGNOSTICS MARKET
    • FIGURE 34 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011-DECEMBER 2022)
    • TABLE 21 LIST OF PATENTS/PATENT APPLICATIONS IN IVD MARKET, 2021-2022
  • 5.9 TRADE ANALYSIS
    • 5.9.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS
    • TABLE 22 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (USD MILLION)
    • TABLE 23 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (TONS)
  • 5.10 ECOSYSTEM ANALYSIS
    • FIGURE 35 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    • 5.10.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.11 VALUE CHAIN ANALYSIS
    • FIGURE 36 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
  • 5.12 SUPPLY CHAIN ANALYSIS
    • FIGURE 37 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
  • 5.13 PRICING ANALYSIS
    • 5.13.1 INDICATIVE AVERAGE SELLING PRICE (USD) REGION-WISE: REAGENTS & KITS
    • 5.13.2 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS
    • 5.13.3 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS
    • 5.13.4 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS
  • 5.14 TECHNOLOGY ANALYSIS
    • 5.14.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
    • 5.14.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
  • 5.15 CASE STUDY
    • FIGURE 38 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 39 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS
    • TABLE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS (%)
    • 5.16.2 BUYING CRITERIA
    • FIGURE 40 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
    • TABLE 25 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
  • 5.17 IMPACT OF RECESSION ON IVD MARKET (2021-2024)
  • 5.18 IMPACT OF IN VITRO DIAGNOSTIC REGULATIONS (IVDR) ON LABORATORY TESTING

6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 26 IN VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 REAGENTS & KITS
    • 6.2.1 GROWING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET
    • TABLE 27 IVD MARKET FOR REAGENTS & KITS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 INSTRUMENTS
    • TABLE 28 KEY INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 29 IVD MARKET FOR INSTRUMENTS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 30 IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.1 FULLY AUTOMATED INSTRUMENTS
      • 6.3.1.1 Rising availability of technologically advanced analyzers to drive market
    • TABLE 31 IVD MARKET FOR FULLY AUTOMATED INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.2 SEMI-AUTOMATED INSTRUMENTS
      • 6.3.2.1 Compact design and cost-effectiveness over automated analyzers to support market growth
    • TABLE 32 IVD MARKET FOR SEMIAUTOMATED INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.3 OTHER INSTRUMENTS
    • TABLE 33 IVD MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.4 DATA MANAGEMENT SOFTWARE
    • 6.4.1 GROWING ADOPTION OF AUTOMATED ANALYZERS AND RISING NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET
    • TABLE 34 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET
    • TABLE 35 IVD MARKET FOR DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 SERVICES
    • 6.5.1 RISING NEED TO ENSURE EFFECTIVE UTILISATION OF IVD PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 36 IVD MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)

7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 37 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 IMMUNOASSAY/IMMUNOCHEMISTRY
    • TABLE 38 KEY IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
    • TABLE 41 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 42 IVD MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 43 IVD MARKET FOR ELISA, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.1.1 Chemiluminescence Immunoassays
        • 7.2.1.1.1 Rising technological advancements and continuous product innovations to drive segment growth
    • TABLE 44 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 45 IVD MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.1.2 Fluorescence Immunoassays
        • 7.2.1.2.1 Rising demand for low-cost fluorescent dyes to drive segment growth
    • TABLE 46 KEY FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 47 IVD MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2020-2027 (USD MILLION)
      • 7.2.1.3 Colorimetric Immunoassays
        • 7.2.1.3.1 High specificity and easy coagulation to antibodies to drive segment growth
    • TABLE 48 KEY COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 49 IVD MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.2 RADIOIMMUNOASSAYS
      • 7.2.2.1 Usage of RIAs in cancer detection, blood screening, and drug discovery to drive market
    • TABLE 50 IVD MARKET FOR RADIOIMMUNOASSAYS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.3 RAPID TESTS
      • 7.2.3.1 Rising usage of rapid tests for emergency care to drive market
    • TABLE 51 KEY RAPID TESTS AVAILABLE IN IVD MARKET
    • TABLE 52 IVD MARKET FOR RAPID TESTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.4 WESTERN BLOTTING
      • 7.2.4.1 Widely accepted technique for result validation to support market growth
    • TABLE 53 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 54 IVD MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
      • 7.2.5.1 High sensitivity and adaptability of technology to fuel market adoption
    • TABLE 55 IVD MARKET FOR ELISPOT ASSAYS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 CLINICAL CHEMISTRY
    • TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
    • TABLE 57 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
    • TABLE 58 KEY BLOOD GAS ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 59 IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.1 BASIC METABOLIC PANELS
      • 7.3.1.1 Set of blood tests performed to ascertain common acute conditions
    • TABLE 61 IVD MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.2 LIVER PANELS
      • 7.3.2.1 Panels used to identify and monitor liver diseases & injuries
    • TABLE 62 IVD MARKET FOR LIVER PANELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.3 RENAL PROFILES
      • 7.3.3.1 Panels used to monitor cytokines & chemokines in urine
    • TABLE 63 IVD MARKET FOR RENAL PROFILES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.4 LIPID PROFILES
      • 7.3.4.1 Lipid panel testing determines total cholesterol and risk status for CVD
    • TABLE 64 IVD MARKET FOR LIPID PROFILES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.5 THYROID FUNCTION PANELS
      • 7.3.5.1 Tests performed to determine TSH and thyroglobulin
    • TABLE 65 IVD MARKET FOR THYROID FUNCTION PANELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.6 ELECTROLYTE PANELS
      • 7.3.6.1 Prescribed for symptoms such as edema, nausea, and cardiac arrhythmia
    • TABLE 66 IVD MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.3.7 SPECIALTY CHEMICAL TESTS
      • 7.3.7.1 Test profile includes immunosuppressant drug monitoring and drugs of abuse
    • TABLE 67 IVD MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 MOLECULAR DIAGNOSTICS
    • TABLE 68 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET
    • TABLE 69 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 70 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.1 POLYMERASE CHAIN REACTION (PCR)
      • 7.4.1.1 Rising prevalence of infectious & viral diseases to drive market
    • TABLE 71 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 72 IVD MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
      • 7.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth
    • TABLE 73 IVD MARKET FOR INAAT, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.3 HYBRIDIZATION
      • 7.4.3.1 Advanced hybridization & automation of data collection techniques to support market growth
    • TABLE 74 IVD MARKET FOR HYBRIDIZATION, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
      • 7.4.4.1 Rising demand for personalized medicine to support market growth
    • TABLE 75 KEY NGS INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 76 IVD MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.5 MICROARRAYS
      • 7.4.5.1 High throughput & resolution capabilities to drive market for protein expression profiling
    • TABLE 77 IVD MARKET FOR MICROARRAYS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
    • TABLE 78 IVD MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 HEMATOLOGY
    • 7.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS TO DRIVE MARKET
    • TABLE 79 KEY HEMATOLOGY ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 80 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.6 MICROBIOLOGY
    • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
    • TABLE 81 KEY MICROBIOLOGY INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 82 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.7 COAGULATION & HEMOSTASIS
    • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET
    • TABLE 83 KEY COAGULATION ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 84 KEY POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN IVD MARKET
    • TABLE 85 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.8 URINALYSIS
    • 7.8.1 RISING PREVALENCE OF KIDNEY DISORDERS AND UTIS TO DRIVE MARKET
    • TABLE 86 KEY URINALYSIS INSTRUMENTS AVAILABLE IN IVD MARKET
    • TABLE 87 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.9 OTHER TECHNOLOGIES
    • TABLE 88 KEY BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN IVD MARKET
    • TABLE 89 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN IVD MARKET
    • TABLE 90 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)

8 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 91 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE ADOPTION OF IVD PRODUCTS
    • TABLE 92 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 DIABETES
    • 8.3.1 RISING PREVALENCE OF DIABETES TO DRIVE ADOPTION OF GLUCOSE MONITORING DEVICES
    • TABLE 93 COUNTRIES WITH A DIABETIC PATIENT POPULATION, 2021 VS. 2045 (MILLION)
    • TABLE 94 IVD MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 ONCOLOGY
    • 8.4.1 RISING INITIATIVES FOR EARLY DETECTION OF CANCER TO DRIVE MARKET
    • TABLE 95 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 CARDIOLOGY
    • 8.5.1 INCREASING USE OF IMMUNOASSAYS IN DETECTION OF CVD TO DRIVE MARKET
    • TABLE 96 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 DRUG TESTING/PHARMACOGENOMICS
    • 8.6.1 INCREASING USE OF TOXICOLOGY TESTING FOR ILLICIT DRUGS TO DRIVE MARKET
    • TABLE 97 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.7 HIV/AIDS
    • 8.7.1 INCREASING USAGE OF REAL-TIME PCR TESTS FOR HIV DETECTION TO DRIVE MARKET
    • TABLE 98 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.8 AUTOIMMUNE DISEASES
    • 8.8.1 GROWING DEMAND FOR PORTABLE POC DIAGNOSTIC DEVICES TO DRIVE MARKET
    • TABLE 99 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.9 NEPHROLOGY
    • 8.9.1 INCREASING USE OF BIOMARKERS FOR CKD TO SUPPORT MARKET GROWTH
    • TABLE 100 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.10 OTHER APPLICATIONS
    • TABLE 101 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 102 IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 HOSPITAL LABORATORIES
    • 9.2.1 RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 103 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 CLINICAL LABORATORIES
    • TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.1 LARGE REFERENCE LABORATORIES
      • 9.3.1.1 Capability to conduct specific tests such as LDTs with advanced diagnostic tools to drive segment growth
    • TABLE 106 LARGE REFERENCE LABORATORIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.2 MEDIUM-SIZED LABORATORIES
      • 9.3.2.1 Increasing adoption of automated instruments to drive growth of this segment
    • TABLE 107 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 9.3.3 SMALL LABORATORIES
      • 9.3.3.1 Adoption of point-of-care devices to support segment growth
    • TABLE 108 SMALL LABORATORIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 POINT-OF-CARE TESTING CENTERS
    • 9.4.1 RISING DEMAND FOR RAPID TESTING AND AVAILABILITY OF INNOVATIVE POINT-OF-CARE IVD PRODUCTS TO DRIVE MARKET
    • TABLE 109 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.5 PATIENTS
    • 9.5.1 USE OF CONVENIENT SELF-TEST KITS TO DRIVE MARKET
    • TABLE 110 IVD MARKET FOR PATIENTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.6 ACADEMIC INSTITUTES
    • 9.6.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH
    • TABLE 111 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.7 OTHER END USERS
    • TABLE 112 IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2027 (USD MILLION)

10 IN VITRO DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 41 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2021)
    • TABLE 113 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 42 NORTH AMERICA: IVD MARKET SNAPSHOT
    • TABLE 114 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 115 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 116 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 NORTH AMERICA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 118 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 119 NORTH AMERICA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 120 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Established reimbursement framework and favorable policies for IVD providers to drive market
    • TABLE 121 US: MACROECONOMIC INDICATORS
    • TABLE 122 US: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 123 US: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 124 US: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 125 US: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 126 US: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 127 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Rising government initiatives & funding for early disease diagnosis to drive market
    • TABLE 128 CANADA: ESTIMATED PREVALENCE OF DIABETES
    • TABLE 129 CANADA: MACROECONOMIC INDICATORS
    • TABLE 130 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 131 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 132 CANADA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 133 CANADA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 134 CANADA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 135 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 136 EUROPE: IVD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 137 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 138 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 139 EUROPE: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 140 EUROPE: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 141 EUROPE: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 142 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Growing investments in clinical diagnostics research to drive market
    • TABLE 143 GERMANY: MACROECONOMIC INDICATORS
    • TABLE 144 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 145 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 146 GERMANY: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 147 GERMANY: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 148 GERMANY: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 149 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.2 FRANCE
      • 10.3.2.1 High healthcare expenditure and rising investments in genomic medicine to drive market
    • TABLE 150 FRANCE: MACROECONOMIC INDICATORS
    • TABLE 151 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 152 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 153 FRANCE: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 154 FRANCE: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 155 FRANCE: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 156 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Rising adoption of genome-based testing and increasing accessibility to IVD tests to drive market
    • TABLE 157 UK: MACROECONOMIC INDICATORS
    • TABLE 158 UK: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 159 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 160 UK: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 161 UK: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 162 UK: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 163 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
    • TABLE 164 ITALY: MACROECONOMIC INDICATORS
    • TABLE 165 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 166 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 167 ITALY: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 168 ITALY: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 169 ITALY: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 170 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising adoption of technologically advanced immunoassay systems to drive market
    • TABLE 171 SPAIN: MACROECONOMIC INDICATORS
    • TABLE 172 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 173 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 174 SPAIN: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 175 SPAIN: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 176 SPAIN: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 177 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.6 RUSSIA
      • 10.3.6.1 Rising incidence of non-communicable diseases and government support for medical services to support market growth
    • TABLE 178 RUSSIA: MACROECONOMIC INDICATORS
    • TABLE 179 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 180 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 181 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 182 RUSSIA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 183 RUSSIA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 184 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 185 REST OF EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 186 REST OF EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 187 REST OF EUROPE: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 188 REST OF EUROPE: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 189 REST OF EUROPE: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 190 REST OF EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 43 ASIA PACIFIC: IVD MARKET SNAPSHOT
    • TABLE 191 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Universal healthcare reimbursement policy and research investments for immunoassays to support market growth
    • TABLE 198 JAPAN: MACROECONOMIC INDICATORS
    • TABLE 199 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 200 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 201 JAPAN: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION))
    • TABLE 202 JAPAN: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 203 JAPAN: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 204 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing awareness of preventive care to drive market for advanced & rapid testing platforms
    • TABLE 205 CHINA: MACROECONOMIC INDICATORS
    • TABLE 206 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 207 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 208 CHINA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 209 CHINA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 210 CHINA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 211 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising incidence of diabetes and cancer to fuel market growth for IVD products
    • TABLE 212 INDIA: MACROECONOMIC INDICATORS
    • TABLE 213 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 214 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 215 INDIA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 216 INDIA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 217 INDIA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 218 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.4 SOUTH KOREA
      • 10.4.4.1 Rising healthcare spending for innovative IVD technologies to support market growth
    • TABLE 219 SOUTH KOREA: MACROECONOMIC INDICATORS
    • TABLE 220 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 221 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 222 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 223 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 224 SOUTH KOREA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 225 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.5 INDONESIA
      • 10.4.5.1 Increasing healthcare initiatives and rising burden of infectious diseases to drive market
    • TABLE 226 INDONESIA: MACROECONOMIC INDICATORS
    • TABLE 227 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 228 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 229 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 230 INDONESIA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 231 INDONESIA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 232 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 233 REST OF ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 234 REST OF ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 235 REST OF ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 236 REST OF ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 238 REST OF ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 239 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 240 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 241 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 242 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 243 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 244 LATIN AMERICA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 245 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Improving healthcare infrastructure to support adoption of IVD products
    • TABLE 246 BRAZIL: MACROECONOMIC INDICATORS
    • TABLE 247 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 248 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 249 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 250 BRAZIL: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 251 BRAZIL: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 252 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Improving accessibility and affordability to healthcare services to support market growth
    • TABLE 253 MEXICO: MACROECONOMIC INDICATORS
    • TABLE 254 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 255 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 256 MEXICO: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 257 MEXICO: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 258 MEXICO: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 259 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 260 REST OF LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 261 REST OF LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 262 REST OF LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 263 REST OF LATIN AMERICA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 264 REST OF LATIN AMERICA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION))
    • TABLE 265 REST OF LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 267 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 268 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 272 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.6.1 SAUDI ARABIA
      • 10.6.1.1 Rising government healthcare expenditure to support adoption of IVD products
    • TABLE 273 SAUDI ARABIA: MACROECONOMIC INDICATORS
    • TABLE 274 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 275 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 276 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 277 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 278 SAUDI ARABIA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 279 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)
    • 10.6.2 REST OF MIDDLE EAST & AFRICA
    • TABLE 280 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 281 REST OF MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 282 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 283 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 284 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 285 REST OF MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 44 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN IVD MARKET
  • 11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS
    • FIGURE 45 REVENUE ANALYSIS FOR KEY PLAYERS IN IVD MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 46 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
    • TABLE 286 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
    • 11.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY
      • 11.4.1.1 Clinical chemistry
    • FIGURE 47 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.2 Immunochemistry/immunoassay analyzers
    • FIGURE 48 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.3 Microbiology
    • FIGURE 49 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.4 Molecular diagnostics
    • FIGURE 50 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.5 Hematology
    • FIGURE 51 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.6 Coagulation & hemostasis
    • FIGURE 52 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
      • 11.4.1.7 Urinalysis
    • FIGURE 53 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
  • 11.5 R&D ASSESSMENT OF KEY PLAYERS
  • 11.6 COMPETITIVE BENCHMARKING
    • TABLE 287 IN VITRO DIAGNOSTIC MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS
  • 11.7 COMPANY EVALUATION QUADRANT
    • 11.7.1 STARS
    • 11.7.2 PERVASIVE PLAYERS
    • 11.7.3 EMERGING LEADERS
    • 11.7.4 PARTICIPANTS
    • FIGURE 54 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT 2021
  • 11.8 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS
    • 11.8.1 PROGRESSIVE COMPANIES
    • 11.8.2 DYNAMIC COMPANIES
    • 11.8.3 STARTING BLOCKS
    • 11.8.4 RESPONSIVE COMPANIES
    • FIGURE 55 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR SMES & STARTUPS
  • 11.9 COMPANY FOOTPRINT ANALYSIS
    • TABLE 288 IVD MARKET: COMPANY FOOTPRINT
    • TABLE 289 COMPANY FOOTPRINT: BY PRODUCT & SERVICE
    • TABLE 290 COMPANY FOOTPRINT: BY TECHNOLOGY
    • TABLE 291 COMPANY FOOTPRINT: BY APPLICATION
    • TABLE 292 COMPANY FOOTPRINT: BY END USER
  • 11.10 COMPETITIVE SCENARIO
    • 11.10.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 293 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-DECEMBER 2022
    • 11.10.2 DEALS
    • TABLE 294 DEALS, JANUARY 2019-DECEMBER 2022
    • 11.10.3 OTHER DEVELOPMENTS
    • TABLE 295 OTHER DEVELOPMENTS, JANUARY 2019-DECEMBER 2022

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 12.1 KEY PLAYERS
    • 12.1.1 ROCHE DIAGNOSTICS
    • TABLE 296 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 56 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
    • 12.1.2 DANAHER CORPORATION
    • TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.3 ABBOTT LABORATORIES, INC.
    • TABLE 298 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 58 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 12.1.4 SIEMENS HEALTHINEERS
    • TABLE 299 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
    • FIGURE 59 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021)
    • 12.1.5 SYSMEX CORPORATION
    • TABLE 300 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 60 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.6 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 301 THERMO FISHER SCIENTIFIC, INC: BUSINESS OVERVIEW
    • FIGURE 61 THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT (2021)
    • 12.1.7 BECTON, DICKINSON AND COMPANY
    • TABLE 302 BD: BUSINESS OVERVIEW
    • FIGURE 62 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
    • 12.1.8 BIOMERIEUX SA
    • TABLE 303 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 63 BIOMERIEUX SA: COMPANY SNAPSHOT (2021)
    • 12.1.9 BIO-RAD LABORATORIES, INC.
    • TABLE 304 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW
    • FIGURE 64 BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT (2021)
    • 12.1.10 AGILENT TECHNOLOGIES, INC.
    • TABLE 305 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 65 AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021)
    • 12.1.11 QIAGEN N.V.
    • TABLE 306 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 66 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.12 QUIDEL CORPORATION
    • TABLE 307 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 67 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.13 DIASORIN S.P.A.
    • TABLE 308 DIASORIN S.P.A: BUSINESS OVERVIEW
    • FIGURE 68 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
    • 12.1.14 ILLUMINA, INC.
    • TABLE 309 ILLUMINA, INC: BUSINESS OVERVIEW
    • FIGURE 69 ILLUMINA, INC: COMPANY SNAPSHOT (2021)
    • 12.1.15 HOLOGIC, INC.
    • TABLE 310 HOLOGIC, INC: BUSINESS OVERVIEW
    • FIGURE 70 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
  • 12.2 OTHER PLAYERS
    • 12.2.1 DEVYSER
    • TABLE 311 DEVYSER: BUSINESS OVERVIEW
    • FIGURE 71 DEVYSER: COMPANY SNAPSHOT (2021)
    • 12.2.2 PERKINELMER INC.
    • TABLE 312 PERKINELMER, INC: BUSINESS OVERVIEW
    • FIGURE 72 PERKINELMER, INC: COMPANY SNAPSHOT (2021)
    • 12.2.3 CHEMBIO DIAGNOSTICS, INC.
    • TABLE 313 CHEMBIO DIAGNOSTICS, INC: BUSINESS OVERVIEW
    • FIGURE 73 CHEMBIO DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021)
    • 12.2.4 SURMODICS, INC.
    • TABLE 314 SURMODICS, INC: BUSINESS OVERVIEW
    • FIGURE 74 SURMODICS, INC: COMPANY SNAPSHOT (2022)
    • 12.2.5 MENARINI SILICON BIOSYSTEMS
    • TABLE 315 MENARINI SILICON BIOSYSTEMS: BUSINESS OVERVIEW
    • 12.2.6 SPEEDX PTY. LTD.
    • 12.2.7 GENSPEED BIOTECH GMBH
    • 12.2.8 ACCELERATE DIAGNOSTICS, INC.
    • 12.2.9 MERCK KGAA
    • 12.2.10 CARIS LIFE SCIENCES, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 CUSTOMIZATION OPTIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS